Hybrid Compounds: Imidazole-Based HO-1 Inhibitors with Sigma Receptor Ligands or Anticancer Drugs
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 September 2023)
Special Issue Editor
Interests: medicinal inorganic chemistry; immunotherapy agents; neuroimaging; anticancer agents; multimodal probes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The recent development of novel imidazole compounds as heme oxygenase-1 (HO-1) inhibitors has received significant attention due to their potent antiproliferative activities. Structure–activity relationship (SAR) studies, along with crystallographic data and docking analyses, have helped generate a vast library of such compounds and contributed to unraveling unique enzyme–ligand binding modes and the identification of lead compounds in this regard. Furthermore, the “combination cocktail” strategy with HO-1 inhibitors and sigma receptor (σR) ligands or antitumor agents has shown synergistic activity in vitro against a wide range of cancer cell lines. Based on these premises, exploring rationally designed hybrid compounds consisting of imidazoles with σR ligands or anticancer drugs is warranted for the discovery of better HO-1 inhibitors. This Special Issue aims to discuss and review recent progress in the synthesis, molecular modeling, delivery technique, and biological evaluation of novel imidazole-based HO-1 inhibitors. We believe this Special Issue will be of significant interest to researchers working on pharmacology and anticancer drug design.
Dr. Sajal Sen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heme oxygenase-1 inhibitors
- imidazole compounds
- sigma receptor ligands
- anticancer agents
- drug design and modification
- molecular docking
- enzyme–ligand interaction
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
